Synthesized V7 QRS Amplitude and Oversensing Episodes in Patients With Subcutaneous Implantable Cardioverter-Defibrillators

被引:0
|
作者
Okajima, Takashi [1 ,2 ]
Ishikawa, Shinji [1 ]
Yanagisawa, Satoshi [2 ,3 ]
Okamoto, Takayuki [1 ]
Uemura, Yusuke [1 ]
Takemoto, Kenji [1 ]
Inden, Yasuya [2 ]
Murohara, Toyoaki [2 ]
Watarai, Masato [1 ]
机构
[1] Anjo Kosei Hosp, Dept Cardiol, Anjo, Japan
[2] Nagoya Univ, Dept Cardiol, Grad Sch Med, Nagoya, Japan
[3] Nagoya Univ, Dept Adv Cardiovasc Therapeut, Grad Sch Med, Nagoya, Japan
来源
关键词
inappropriate shock therapies; oversensing episodes; QRS amplitude; subcutaneous implantable cardioverter-defibrillator; synthesized 18-lead electrocardiogram; EFFICACY; SAFETY; ORIGIN;
D O I
10.1111/pace.15086
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundPatients with subcutaneous implantable cardioverter-defibrillators (S-ICDs) experience an oversensing episode (OS) more frequently than those with transvenous ICDs. However, no established electrocardiography (ECG) parameters can accurately detect an OS. This study aimed to evaluate the incidence of an OS in real-world clinical practice and the association of synthesized 18-lead ECG (syn18-ECG) parameters with an OS. MethodsWe retrospectively included 21 consecutive patients who underwent S-ICD implantation and collected syn18-ECG parameters. We placed the generator in a deep posterior position and defined an OS as an inappropriate charging episode caused by cardiac or noncardiac signals. A SMART pass filter and two tachyarrhythmia zones were programed. ResultsThe most frequent underlying heart disease was Brugada/J wave syndrome (n = 7). During a median follow-up period of 1188 days, an OS was observed in six patients (28.6%). The QRS amplitude in synthesized V7 lead (synV7) was significantly lower in the OS group than in the non-OS group (0.59 +/- 0.17 vs. 0.91 +/- 0.35 mV, p = 0.019). The optimal cutoff value of synV7 QRS amplitude was 0.61 mV, with a sensitivity of 80.0% and a specificity of 83.7% for predicting an OS. Univariate logistic analysis showed that a synV7 QRS amplitude of <0.61 mV was only associated with an OS (odd ratio, 20.0; 95% confidence interval, 1.66-241.72; p = 0.018). ConclusionsIn patients with S-ICDs, an OS was not a rare complication during long-term follow-up. A low synV7 QRS amplitude was associated with a high OS incidence.
引用
收藏
页码:1565 / 1573
页数:9
相关论文
共 50 条
  • [11] ECG predictors of T wave oversensing in subcutaneous implantable cardioverter defibrillators
    Wilson, D. G.
    Leventigiannis, G.
    Barr, C.
    Morgan, J. M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 220 : 27 - 31
  • [12] Implantable Cardioverter-Defibrillators in Patients With COPD
    Naksuk, Niyada
    Kunisaki, Ken M.
    Benditt, David G.
    Tholakanahalli, Venkatakrishna
    Adabag, Selcuk
    CHEST, 2013, 144 (03) : 778 - 783
  • [13] Implantable cardioverter-defibrillators in dialysis patients
    Mills, Mark T.
    BMJ EVIDENCE-BASED MEDICINE, 2020, 25 (05) : 187 - 188
  • [14] TRANSVENOUS AND SUBCUTANEOUS IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS - RADIOGRAPHIC ASSESSMENT
    DALY, BD
    CASCADE, PN
    HUMMEL, JD
    KALBFLEISCH, S
    STRICKBERGER, SA
    LANGBERG, J
    MORADY, F
    RADIOLOGY, 1994, 191 (01) : 273 - 278
  • [15] Subcutaneous implantable cardioverter-defibrillators: Function, indications and implantation
    Osswald B.
    Zeitschrift für Herz-,Thorax- und Gefäßchirurgie, 2017, 31 (3) : 155 - 160
  • [16] Accelerated Battery Depletion in Subcutaneous Implantable Cardioverter-Defibrillators
    Narayanan, Chockalingam A.
    Katcher, Benjamin
    Coleman, Stephanie
    Butts, Laurie
    Homoud, Munther K.
    Garlitski, Ann C.
    Weinstock, Jonathan
    Link, Mark S.
    Madias, Christopher
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2021, 7 (06) : 806 - 808
  • [17] MORE ON PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
    EMBIL, JM
    GEDDES, JS
    ANNALS OF INTERNAL MEDICINE, 1995, 123 (11) : 892 - 893
  • [18] Effect of diurnal variations in the QRS complex and T waves on the eligibility for subcutaneous implantable cardioverter-defibrillators
    Miwa, Naoyuki
    Nagata, Yasutoshi
    Yamaguchi, Tetsuo
    Nagase, Masashi
    Sasaki, Takeshi
    Nozato, Toshihiro
    Ashikaga, Takashi
    Goya, Masahiko
    Hirao, Kenzo
    HEART RHYTHM, 2019, 16 (06) : 913 - 920
  • [19] Causes of ventricular oversensing in implantable cardioverter-defibrillators: Implications for diagnosis of lead fracture
    Gunderson, Bruce D.
    Swerdlow, Charles D.
    Wilcox, Jay M.
    Hayman, Jean E.
    Ousdigian, Kevin T.
    Ellenbogen, Kenneth A.
    HEART RHYTHM, 2010, 7 (05) : 626 - 633
  • [20] Perioperative Considerations for Patients With Subcutaneous Implantable Cardioverter-Defibrillators Undergoing Noncardiac Surgery
    Essandoh, Michael
    Daoud, Emile G.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2016, 30 (03) : 756 - 761